SCHEMBL1202604

SCHEMBL1202604

CCC(C(=O)O)c1ccc(I)c(OCC2CC2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 7/20 0.45
AKR1C2 P52895 7/20 0.45
AKR1C1 Q04828 2/20 0.45
PTGS1 P23219 1/20 0.45
PDE4B Q07343 7/20 0.40
KEAP1 Q14145 2/20 0.39
NFE2L2 Q16236 2/20 0.39
GPR88 Q9GZN0 1/20 0.38
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
FFAR1 O14842 1/20 0.38
PDE4A P27815 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
AKR1B10 O60218 1/20 0.37
AKR1C4 P17516 1/20 0.37
S1PR2 O95136 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202625 0.85 AKR1C3 (0.45) AKR1C3AKR1C2AKR1C1PTGS1PDE4B
SCHEMBL1201730 0.81 PDE4B (0.39) PDE4BKEAP1NFE2L2GPR88ACACB
SCHEMBL1202823 0.81 PDE4B (0.44) AKR1C3AKR1C2AKR1C1PTGS1PDE4B
SCHEMBL1202825 0.81 PDE4B (0.44) AKR1C3AKR1C2AKR1C1PTGS1PDE4B
SCHEMBL1202501 0.77 APP (0.60) AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4
SCHEMBL3658630 0.75 APP (0.44) PDE4BPDE4APDE4CPDE4DS1PR2
SCHEMBL15111261 0.74 PDE4B (0.41) PDE4BKEAP1NFE2L2GPR88ACACB
SCHEMBL8051796 0.74 THRA (0.47) PDE4BPDE4APDE4CPDE4D
SCHEMBL15111389 0.74 APP (0.48) PDE4BKEAP1NFE2L2GPR88ACACB
SCHEMBL12070242 0.72 HSP90AA1 (0.49) PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140187786-A1 1,3,4-TRISUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS, INC. (US) 2014-07-03 US disclosed
US-20110040094-A1 1,3,4-TRISUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed
WO-2009036428-A2 1,3,4-TRISUBSTITUTED BENZENES ENVIVO PHARMACEUTICALS, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110040094-A1 1,3,4-TRISUBSTITUTED BENZENES BACE1, BACE2, PSEN1 AKR1C3 3717/4885AKR1C2 3410/4885AKR1C1 3429/4885
US-20140187786-A1 1,3,4-TRISUBSTITUTED BENZENES BACE1, BACE2, PSEN1 AKR1C3 3717/4885AKR1C2 3410/4885AKR1C1 3429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.